Leontopodium species: Phytochemistry, biosynthesis, synthesis, pharmacology, and synthetic advancement
- PMID: 40328374
- DOI: 10.1016/j.fitote.2025.106584
Leontopodium species: Phytochemistry, biosynthesis, synthesis, pharmacology, and synthetic advancement
Abstract
Leontopodium (the daisy family) is a well-known genus containing medicinal plants for potent antioxidant and skin protection. An overview of its several aspects is not available. The current study aims to offer the state-of-the-art of its phytochemistry, biosynthesis, synthesis, pharmacology, and synthetic advancement. The search for English references has relied on several main electronic sources: PubMed and Web of Science. The "SCI-Finder" was used to confirm chemical structures. The best keyword, "Leontopodium", was frequently used in finding literature. Data collection was performed from the 1970s to the present. A diverse structural phytochemicals (179 compounds) were recorded, such as flavonoids, phenolic acids, terpenoids, phthalides, lignans, and coumarins. Leontopodium constituents are essential for anti-inflammation, antioxidant, and living organ protection. The biosynthesis and synthesis of several metabolites were successfully proposed. Leolignin has played a great role in pharmacological evaluations, while its synthetic products has shown cardioprotective and farnesoid X receptor (FXR) agonistic enhancements. Technological advancements in the isolation and new synthetic production are expected. Although several clinical studies have been conducted, more and more trials are needed.
Keywords: Asteraceae; Biosynthesis; Leontopodium; Pharmacology; Phytochemistry; Synthesis.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no conflict of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources